Neuromodulation Devices Global Market- Forecast to 2029
Publishing Date : | September, 2022 |
Report Code : | HCMD0131 |
Price: |
Single license $4,950
Site license $6,750 Global license $9,000 |
Neuromodulation treatment involves direct stimulation or modulation of the nerves by an electrical or magnetic field. It is used as a treatment for unmanageable chronic pain, movement disorders, neurological diseases, gastroenterology, respiratory related diseases and others. The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches. This therapy is based on the natural process of stimulation of nerve cell activity and release of neurotransmitters that regulate nerve activity. Neuromodulation is gaining popularity because these devices have been very successful in the treatment of conditions for which medicines have failed completely or may have unpleasant side effects.
The neuromodulation global market is expected to grow at a high single digit CAGR from 2022 to 2029 to reach $9,569.4 million by 2029 due to increasing incidence of chronic pain, increasing parkinson’s and alzheimer’s disorders, low approval rate of CNS drugs, favorable reimbursement scenario in major markets, the emergence of neuromodulation as add-on therapy, technological innovations, rise in the number of clinical studies performed and expansion in emerging markets. The neuromodulation devices market is segmented into product, application, end-user, and geography.
Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices. Among these, invasive neuromodulation devices segment accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2029. Invasive neuromodulation devices market is segmented into Spinal Cord Stimulator (SCS), Deep Brain Stimulator (DBS), Sacral Nerve Stimulator (SNS), Vagus Nerve Stimulator (VNS), Hypoglossal Nerve Stimulator (HGNS) and others include Gastric Electric Stimulation (GES), Respiratory Electrical Stimulation (RES) or Phrenic Nerve Stimulation (PNS). Among invasive neuromodulation devices, Spinal cord stimulator (SCS) segment accounted for the largest revenue in 2022 and is expected to grow at a mid-single digit CAGR from 2022 to 2029 due to increase in the incidence of chronic pain, increase in movement disorders and high implantation rate of spinal cord stimulators. The Hypoglossal Nerve Stimulator segment is expected to grow at a high double digit CAGR from 2022 to 2029. The non-invasive neuromodulation devices market is segmented into Transcutaneous Electrical Nerve Stimulation (TENS), Neuromuscular Electrical Stimulation (NMES) and others. Among these, Transcutaneous Electrical Nerve Stimulator (TENS) segment is the largest and fastest growing segment accounted for the highest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029.
Based on the application, the neuromodulation devices global market is segmented into Pain Management, Central Nervous System, Gastroenterology and Urology, Obstructive Sleep Apnea (OSA) and other applications include Obesity, Heart Failure, Autoimmune diseases (rheumatoid arthritis), respiratory related diseases (diaphragm pacing), Diabetes and Weaning. Among these, pain management segment accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. Obstructive Sleep Apnea segment is expected to grow at a high double digit CAGR from 2022 to 2029.
Pain management is further segmented into chronic pain, failed back surgery syndrome (FBSS) and others. Among these, chronic pain segment accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029 due to increasing incidence of chronic pain, increasing utilizing of the spinal cord stimulators and advancement in neuromodulation devices.
Central Nervous System is further segmented into Parkinson’s disease, Dystonia, Epilepsy and others include Obsessive Compulsive Disorder (OCD), Depression, Stroke, and Mood disorders, Anxiety, Central Sleep Apnea and Multiple Sclerosis. Among these, Parkinson’s disease segment accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. Epilepsy segment is expected to grow at a high double digit CAGR from 2022 to 2029.
Gastroenterology and Urology is further segmented into Gastroparesis, Urinary Incontinence and Faecal Incontinence. Among these, Urinary Incontinence segment accounted for the largest revenue in 2022 and is expected to grow at a mid-single digit CAGR from 2022 to 2029.
Based on the end-user, the neuromodulation devices global market is segmented into Hospitals and Ambulatory Surgery Centers, Clinics and Physiotherapy Centers and Others include Home care, Academics and Research Institutes. Among these, Hospitals and Ambulatory Surgery Centers is the largest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029.
Based on the region, the neuromodulation devices global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and Middle East & others). North America accounted for the largest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029 due to high technological advancements, increased growing awareness about medical care, treatment style, increase in the aging population, strong product pipeline, new indications, investments and funds, increases in neurological diseases, sophisticated infrastructure related to healthcare and high expenditure present among the population of North America are boosting the market of neuromodulation devices. Asia-Pacific is the fastest growing segment accounted for the highest revenue in 2022 and is expected to grow at a high double digit CAGR from 2022 to 2029 due to rising incidences of neurological disorders, government initiatives to increasing awareness by education campaigns, large pool of patients, increasing geriatric population, advancements in surgeries and technologies, increased healthcare facilities, increasing adoption of implantable devices, high acceptance of technological advancements, the easy availability of advanced healthcare technology, skilled personnel and low-cost for the surgery are driving the market.
The neuromodulation devices global market is a highly consolidated market hence all the existing players in this market are involved in developing new and advanced technologies to maintain their market shares. Some of the major players in Neuromodulation devices market include Abbott Laboratories (U.S.), Axonics Inc. (U.S.), Bioventus (Bioness Inc.) (U.S.), Boston Scientific Corporation (U.S.), Inspire Medical System Inc. (U.S.), Laborie Medical (Canada), LivaNova Plc (U.K.), Medtronic Plc (Ireland), NeuroPace Inc. (U.S.) and Nevro Corporation (U.S.).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
- North America
- U.S.
- Rest of North America
- Europe
- Germany
- France
- U.K.
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of APAC
- Rest of the World (RoW)
- Brazil
- Rest of Latin America
- Middle East and Others
- 1 EXECUTIVE SUMMARY
- 2 INTRODUCTION
- 2.1 KEY TAKEAWAYS
- 2.2 SCOPE OF THE REPORT
- 2.3 REPORT DESCRIPTION
- 2.4 MARKETS COVERED
- 2.5 STAKEHOLDERS
- 2.6 RESEARCH METHODOLOGY
- 2.6.1 MARKET SIZE ESTIMATION
- 2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.6.3 SECONDARY SOURCES
- 2.6.4 PRIMARY SOURCES
- 2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
- 2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
- 2.6.7 ASSUMPTIONS
- 3 MARKET ANALYSIS
- 3.1 INTRODUCTION
- 3.2 MARKET SEGMENTATION
- 3.3 FACTORS INFLUENCING MARKET
- 3.3.1 DRIVERS AND OPPORTUNITIES
- 3.3.1.1. GROWING PREVALENCE OF TREATMENT RESISTANT CHRONIC CONDITIONS TO FUEL THE DEMAND FOR NEUROMODULATION DEVICES
- 3.3.1.2. GROWING PREVALENCE OF PARKINSON'S, ALZHEIMER'S DISEASES, NEUROLOGICAL AND RESPIRATORY CONDITIONS TO DRIVE THE MARKET
- 3.3.1.3. LOW APPROVAL RATE OF CNS DRUGS IS DRIVING NEUROMODULATION MARKET
- 3.3.1.4. FAVORABLE REIMBURSEMENT SCENARIO IN MAJOR MARKETS
- 3.3.1.5. THE EMERGENCE OF NEUROMODULATION AS ADD-ON THERAPY
- 3.3.1.6. TECHNOLOGICAL AINNOVATIONS IN NEUROMODULATION
- 3.3.1.7. EXPANSION IN EMERGING MARKETS
- 3.3.1.8. THE RISE IN THE NUMBER OF CLINICAL STUDIES PERFORMED
- 3.3.2 RESTRAINTS AND THREATS
- 3.3.2.1 SIDE EFFECTS AND RISK ASSOCIATED WITH THE USE
- 3.3.2.2 LACK OF TRAINED PROFESSIONALS
- 3.3.2.3 AVAILABILITY OF ALTERNATIVE TREATMENTS
- 3.3.2.4 STRINGENT REGULATORY GUIDELINES
- 3.4 REGULATORY AFFAIRS
- 3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
- 3.4.1.1 ISO 9001: 2015 Quality Management system
- 3.4.1.2 ISO 13485 Medical devices
- 3.4.1.3 ISO 10993 Biological evaluation of medical devices
- 3.4.2 U.S.
- 3.4.3 CANADA
- 3.4.4 EUROPE
- 3.4.5 JAPAN
- 3.4.6 CHINA
- 3.4.7 INDIA
- 3.5 CLINICAL TRIALS DATA
- 3.6 TECHNOLOGICAL ADVANCEMENTS
- 3.6.1 RECHARGEABLE SYSTEMS
- 3.6.2 OPTOGENETIC TECHNOLOGY
- 3.6.3 FOCUSED ULTRASOUND (FUS)
- 3.6.4 MINIATURIZATION
- 3.6.5 PORTABLE NUEROMODULATION SYSTEMS (PONS)
- 3.6.6 WEARABLE PAIN MANAGEMENT TECHNOLOGY
- 3.6.7 TRANS-SPINAL DIRECT CURRENT STIMULATION (TSDCS)
- 3.6.8 NANO-NEUROMODULATION
- 3.6.9 BIOACTIVE COATINGS
- 3.6.10 OCCIPITAL NERVE STIMULATION (ONS)
- 3.6.11 CRANIAL ELECTROTHERAPY STIMULATION (CES)
- 3.7 PORTER’S FIVE FORCE ANALYSIS
- 3.7.1 THREAT OF NEW ENTRANTS
- 3.7.2 THREAT OF SUBSTITUTES
- 3.7.3 BARGAINING POWER OF SUPPLIERS
- 3.7.4 BARGAINING POWER OF BUYERS
- 3.7.5 COMPETITIVE RIVALRY
- 3.8 SUPPLY CHAIN ANALYSIS
- 3.9 IMPACT OF COVID-19 ON NEUROMODULATION DEVICES
- 3.1 REIMBURSEMENT SCENARIO
- 3.10.1 REIMBURSEMENT TABLE
- 3.11 REGULATORY APPROVED NEUROMODULATION DEVICES
- 3.11.1 SPINAL CORD STIMULATORS (SCS)
- 3.11.2 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS)
- 3.11.3 DEEP BRAIN STIMULATION (DBS)
- 3.11.4 SACRAL NERVE STIMULATION (SNS)
- 3.11.5 VAGUS NERVE STIMULATION (VNS)
- 3.11.6 TRANSCRANIAL MAGNETIC STIMULATION (TMS)
- 3.12 FUNDING SCENARIO
- 3.13 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
- 3.13.1 NEUROMODULATION DEVICES GLOBAL MARKET SHARE ANALYSIS
- 3.13.2 SPINAL CORD STIMULATORS GLOBAL MARKET SHARE ANALYSIS
- 3.13.3 DEEP BRAIN STIMULATORS GLOBAL MARKET SHARE ANALYSIS
- 3.13.4 SACRAL NERVE STIMULATOR (SNS) GLOBAL MARKET SHARE ANALYSIS
- 3.13.5 HYPOGLOSSAL NERVE STIMULATOR (HGNS) GLOBAL MARKET SHARE ANALYSIS
- 3.14 NEUROMODULATION DEVICES NUMBER OF UNITS BASED ON REGION
- 3.14.1 SPINAL CORD STIMULATION (SCS) NUMBER OF UNITS BASED ON REGION
- 3.14.2 DEEP BRAIN STIMULATION (DBS) NUMBER OF UNITS BASED ON REGION
- 3.14.3 SACRAL NERVE STIMULATION (SNS) NUMBER OF UNITS
- 3.14.4 VAGUS NERVE STIMULATION (VNS) NUMBER OF UNITS BEASED ON REGION
- 3.14.5 HYPOGLOSSAL NERVE STIMULATION (HGNS) NUMBER OF UNITS BASED ON REGION
- 3.15 MARKET PENETRATION
- 3.15.1 UNITED STATES OBSTRUCTIVE SLEEP APNEA NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
- 3.15.2 UNITED STATES DRUG RESISTANT EPILEPSY NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
- 3.15.3 UNITED STATES DEPRESSION NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
- 3.15.4 UNITED STATES OVERACTIVE BLADDER NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
- 3.15.5 UNITED STATES CHRONIC PAIN NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
- 3.16 NEUROMODULATION DEVICES COMPANY COMPARISON TABLE BY REVENUE, TECHNOLOGY, PRODUCTS AND APPLICATION
- 4.1 INTRODUCTION
- 4.2 INVASIVE NEUROMODULATION DEVICES
- 4.2.1 SPINAL CORD STIMULATION (SCS)
- 4.2.2 DEEP BRAIN STIMULATION (DBS)
- 4.2.3 SACRAL NERVE STIMULATION (SNS)
- 4.2.4 VAGUS NERVE STIMULATION (VNS)
- 4.2.5 HYPOGLOSSAL NERVE STIMULATION (HGNS)
- 4.2.6 OTHER INVASIVE NEUROMODULATION DEVICES
- 4.2.6.1 GASTRIC ELECTRIC STIMULATION (GES)
- 4.2.6.2 RESPIRATORY ELECTRICAL STIMULATION (RES)/PHRENIC NERVE STIMULATION (PNS)
- 4.3 NON-INVASIVE NEUROMODULATION DEVICES
- 4.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
- 4.3.2 NEUROMUSCULAR ELECTRICAL STIMULATION (NMES)
- 4.3.3 OTHER NON-INVASIVE NEUROMODULATION DEVICES
- 4.3.3.1 TRANSCRANIAL MAGNETIC STIMULATION (TMS)
- 4.3.3.2 FUNCTIONAL ELECTRICAL STIMULATION (FES)
- 4.3.3.3 ELECTROCONVULSIVE THERAPY (ECT)
- 4.3.3.4 PERCUTANEOUS TIBIAL NERVE STIMULATION (PTNS)
- 4.3.3.5 PORTABLE NEUROMODULATION STIMULATION (PONS)
- 4.3.3.6 TRANSCRANIAL ELECTRICAL STIMULATION (TES)
- 4.3.3.7 TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
- 4.3.3.8 TRANSCRANIAL ALTERNATING CURRENT STIMULATION (TACS)
- 4.3.3.9 PERIPHERAL NERVE STIMULATION (PNS)
- 4.3.3.10 TRIGEMINAL NERVE STIMULATION (TNS)
- 4.3.3.11 COORDINATED RESET NEUROMODULATION (CR NEUROMODULATION)
- 4.3.3.12 PERCUTANEOUS ELECTRICAL NERVE STIMULATION (PENS)
- 4.3.3.13 TRANSCRANIAL ELECTROMAGNETIC TREATMENT (TEMT)
- 4.3.3.14 PERCUTANEOUS ELECTRIC NERVE FIELD STIMULATION (PENFS)
- 4.3.3.15 TRANSCUTANEOUS SUPRAORBITAL NEUROSTIMULATION (TSNS)
- 4.3.3.16 OCCIPITAL NERVE STIMULATION (ONS)
- 4.3.3.17 CRANIAL ELECTROTHERAPY STIMULATION (CES)
- 5.1 INTRODUCTION
- 5.2 PAIN MANAGEMENT
- 5.2.1 CHRONIC PAIN
- 5.2.2 FAILED BACK SURGERY SYNDROME (FBSS)
- 5.2.3 OTHER PAIN MANAGEMENT
- 5.3 CENTRAL NERVOUS SYSTEM (CNS)
- 5.3.1 PARKINSON'S DISEASE
- 5.3.2 DYSTONIA
- 5.3.3 EPILEPSY
- 5.3.4 OTHERS
- 5.4 GASTROENTEROLOGY AND UROLOGY
- 5.4.1 GASTROPARESIS
- 5.4.2 URINARY INCONTINENCE
- 5.4.3 FAECAL INCONTINENCE
- 5.5 OBSTRUCTIVE SLEEP APNEA (OSA)
- 5.6 OTHER APPLICATIONS
- 6.1 INTRODUCTION
- 6.2 HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC)
- 6.3 CLINICS AND PHYSIOTHERAPY CENTERS
- 6.4 OTHERS (HOME CARE, ACADEMICS AND RESEARCH INSTITUTES)
- 7.1 INTRODUCTION
- 7.2 NORTH AMERICA
- 7.2.1 UNITED STATES (U.S.)
- 7.2.2 REST OF NORTH AMERICA
- 7.3 EUROPE
- 7.3.1 GERMANY
- 7.3.2 FRANCE
- 7.3.3 UNITED KINGDOM (U.K.)
- 7.3.4 REST OF EUROPE
- 7.4 APAC
- 7.4.1 JAPAN
- 7.4.2 CHINA
- 7.4.3 INDIA
- 7.4.4 REST OF APAC
- 7.5 REST OF THE WORLD (ROW)
- 7.5.1 BRAZIL
- 7.5.2 REST OF LATIN AMERICA (LATAM)
- 7.5.3 MIDDLE EAST AND OTHERS
- 8.1 INTRODUCTION
- 8.2 PRODUCT APPROVAL
- 8.3 PRODUCT LAUNCH
- 8.4 EXPANSION AND ACQUISITION
- 8.5 AGREEMENT AND COLLABORATION
- 8.6 OTHER DEVELOPMENTS
- 9.1 ABBOTT LABORATORIES
- 9.1.1 OVERVIEW
- 9.1.2 FINANCIALS
- 9.1.3 PRODUCT PORTFOLIO
- 9.1.4 KEY DEVELOPMENTS
- 9.1.5 BUSINESS STRATEGY
- 9.1.6 SWOT ANALYSIS
- 9.2 AXONICS INC.
- 9.2.1 OVERVIEW
- 9.2.2 FINANCIALS
- 9.2.3 PRODUCT PORTFOLIO
- 9.2.4 KEY DEVELOPMENTS
- 9.2.5 BUSINESS STRATEGY
- 9.2.6 SWOT ANALYSIS
- 9.3 BIOVENTUS (BIONESS INC)
- 9.3.1 OVERVIEW
- 9.3.2 FINANCIALS
- 9.3.3 PRODUCT PORTFOLIO
- 9.3.4 KEY DEVELOPMENTS
- 9.3.5 BUSINESS STRATEGY
- 9.3.6 SWOT ANALYSIS
- 9.4 BOSTON SCIENTIFIC CORPOARTION
- 9.4.1 OVERVIEW
- 9.4.2 FINANCIALS
- 9.4.3 PRODUCT PORTFOLIO
- 9.4.4 KEY DEVELOPMENTS
- 9.4.5 BUSINESS STRATEGY
- 9.4.6 SWOT ANALYSIS
- 9.5 INSPIRE MEDICAL SYSTEM, INC.
- 9.5.1 OVERVIEW
- 9.5.2 FINANCIALS
- 9.5.3 PRODUCT PORTFOLIO
- 9.5.4 KEY DEVELOPMENTS
- 9.5.5 BUSINESS STRATEGY
- 9.5.6 SWOT ANALYSIS
- 9.6 LABORIE MEDICAL TECHNOLOGIES, INC. (COGENTIX MEDICAL)
- 9.6.1 OVERVIEW
- 9.6.2 FINANCIALS
- 9.6.3 PRODUCT PORTFOLIO
- 9.6.4 KEY DEVELOPMENTS
- 9.6.5 BUSINESS STRATEGY
- 9.6.6 SWOT ANALYSIS
- 9.7 LIVANOVA PLC (SORIN GROUP)
- 9.7.1 OVERVIEW
- 9.7.2 FINANCIALS
- 9.7.3 PRODUCT PORTFOLIO
- 9.7.4 KEY DEVELOPMENTS
- 9.7.5 BUSINESS STRATEGY
- 9.7.6 SWOT ANALYSIS
- 9.8 MEDTRONIC PLC
- 9.8.1 OVERVIEW
- 9.8.2 FINANCIALS
- 9.8.3 PRODUCT PORTFOLIO
- 9.8.4 KEY DEVELOPMENTS
- 9.8.5 BUSINESS STRATEGY
- 9.8.6 SWOT ANALYSIS
- 9.9 NEUROPACE, INC.
- 9.9.1 OVERVIEW
- 9.9.2 FINANCIALS
- 9.9.3 PRODUCT PORTFOLIO
- 9.9.4 KEY DEVELOPMENTS
- 9.9.5 BUSINESS STRATEGY
- 9.9.6 SWOT ANALYSIS
- 9.1 NEVRO CORPOARTION
- 9.10.1 OVERVIEW
- 9.10.2 FINANCIALS
- 9.10.3 PRODUCT PORTFOLIO
- 9.10.4 KEY DEVELOPMENTS
- 9.10.5 BUSINESS STRATEGY
- 9.10.6 SWOT ANALYSIS
- TABLE 1 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 2 SCS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
- TABLE 3 DBS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
- TABLE 4 SNS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
- TABLE 5 VNS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
- TABLE 6 VNS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
- TABLE 7 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
- TABLE 8 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 9 INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
- TABLE 10 INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 11 SPINAL CORD STIMULATION (SCS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 12 DEEP BRAIN STIMULATION (DBS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 13 SACRAL NERVE STIMULATION (SNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 14 VAGUS NERVE STIMULATION (VNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 15 HYPOGLOSSAL NERVE STIMULATION (HGNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 16 OTHER INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 17 NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
- TABLE 18 NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 19 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 20 NEUROMUSCULAR ELECTRICAL STIMULATION (NMES) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 21 OTHER NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 22 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
- TABLE 23 PAIN MANAGEMENT GLOBAL MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 24 PAIN MANAGEMENT GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 25 CHRONIC PAIN GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 26 FAILED BACK SURGERY SYNDROME (FBSS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 27 OTHER PAIN MANAGEMENT GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 28 CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 29 CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 30 PARKINSON'S DISEASE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 31 DYSTONIA GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 32 EPILEPSY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 33 OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 34 GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 35 GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 36 GASTROPARESIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 37 URINARY INCONTINENCE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 38 FAECAL INCONTINENCE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 39 OBSTRUCTIVE SLEEP APNEA GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 40 OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 41 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
- TABLE 42 HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 43 CLINICS AND PHYSIOTHERAPY CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 44 OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 45 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
- TABLE 46 NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
- TABLE 47 NORTH AMERICA INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
- TABLE 48 NORTH AMERICA NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
- TABLE 49 NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
- TABLE 50 NORTH AMERICA PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 51 NORTH AMERICA CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 52 NORTH AMERICA GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 53 NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
- TABLE 54 NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
- TABLE 55 UNITED STATES NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 56 REST OF NORTH AMERICA NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 57 EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
- TABLE 58 EUROPE INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
- TABLE 59 EUROPE NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
- TABLE 60 EUROPE NEUROMODULATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
- TABLE 61 EUROPE PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 62 EUROPE CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 63 EUROPE GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 64 EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
- TABLE 65 EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
- TABLE 66 GERMANY NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 67 FRANCE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 68 UNITED KINGDOM NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 69 REST OF EUROPE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 70 APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
- TABLE 71 APAC INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
- TABLE 72 APAC NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
- TABLE 73 APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
- TABLE 74 APAC PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 75 APAC CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 76 APAC GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 77 APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
- TABLE 78 APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
- TABLE 79 JAPAN NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 80 CHINA NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 81 INDIA NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 82 REST OF APAC NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 83 ROW NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
- TABLE 84 ROW INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
- TABLE 85 ROW NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
- TABLE 86 ROW NEUROMODULATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
- TABLE 87 ROW PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 88 ROW CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 89 ROW GASTROENTEROLOGY AND UROLOGY MARKETREVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
- TABLE 90 ROW NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
- TABLE 91 ROW NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
- TABLE 92 BRAZIL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 93 REST OF LATAM NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 94 MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
- TABLE 95 PRODUCT APPROVAL (2020-2022)
- TABLE 96 PRODUCT LAUNCH (2020-2022)
- TABLE 97 EXPANSION AND ACQUISITION (2020-2022)
- TABLE 98 AGREEMENT AND COLLABORATION (2020-2022)
- TABLE 99 OTHER DVELOPMENTS (2020-2022)
- TABLE 100 ABBOTT LABORATORIES.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
- TABLE 101 ABBOTT LABORATORIES.: TOTAL REVENUE, BASED ON SEGMENT, (2019-2021) ($MN)
- TABLE 102 ABBOTT LABORATORIES.: TOTAL REVENUE, BASED ON SUB-SEGMENT, (2019-2021) ($MN)
- TABLE 103 ABBOTT LABORATORIES.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2019-2021) ($MN)
- TABLE 104 AXONICS INC.: TOTAL REVENUE AND R&D EXPENSES (2020-2022 (Q1)) ($MN)
- TABLE 105 AXONICS INC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q1)) ($MN)
- TABLE 106 AXONICS INC.: TOTAL REVENUE, BASED ON REGION, (2020-2022 (Q1)) ($MN)
- TABLE 107 BIOVENTUS.: TOTAL REVENUE AND R&D EXPENSES (2020-2022 (Q1)) ($MN)
- TABLE 108 BIOVENTUS.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q1)) ($MN)
- TABLE 109 BIOVENTUS.: TOTAL REVENUE, BASED ON REGION, (2020-2022 (Q1)) ($MN)
- TABLE 110 BOSTON SCIENTIFIC CORPORATION : TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q1)) ($MN)
- TABLE 111 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q1)) ($MN)
- TABLE 112 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-202 (Q1)) ($MN)
- TABLE 113 INSPIRE MEDICAL SYSTEM, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q1)) ($MN)
- TABLE 114 INSPIRE MEDICAL SYSTEM,INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022 (Q1)) ($MN)
- TABLE 115 LIVANOVA PLC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q1)) ($MN)
- TABLE 116 LIVANOVA PLC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q1)) ($MN)
- TABLE 117 LIVANOVA PLC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022 (Q1)) ($MN)
- TABLE 118 MEDTRONIC, PLC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q3)) ($MN)
- TABLE 119 MEDTRONIC, PLC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q3)) ($MN)
- TABLE 120 MEDTRONIC, PLC.: TOTAL REVENUE, BASED ON SUB-SEGMENT (NEUROSCIENCE)(2020-2022 (Q3)) ($MN)
- TABLE 121 MEDTRONIC, PLC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022 (Q3)) ($MN)
- TABLE 122 NEUROPACE, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q1)) ($MN)
- TABLE 123 NEVRO CORPORATION : TOTAL REVENUE AND R&D EXPENSES (2020-2022 (Q1)) ($MN)
- TABLE 124 NEVRO CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022 (Q1)) ($MN)
- FIGURE 1 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
- FIGURE 2 RESEARCH METHODOLOGY: NEUROMODULATION DEVICES GLOBAL MARKET
- FIGURE 3 NEUROMODULATION DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
- FIGURE 4 NEUROMODULATION DEVICES GLOBAL MARKET: FORECASTING MODEL
- FIGURE 5 NEUROMODULATION DEVICES GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
- FIGURE 6 NEUROMODULATION DEVICES GLOBAL MARKET SEGMENTATION
- FIGURE 7 MARKET DYNAMICS
- FIGURE 8 NEUROMODULATION DEVICES CLINICAL TRIAL ANALYSIS
- FIGURE 9 NEUROMODULATION DEVICES GLOBAL MARKET: PORTER’S ANALYSIS
- FIGURE 10 NEUROMODULATION DEVICES: SUPPLY CHAIN ANALYSIS
- FIGURE 11 NEUROMODULATION DEVICES GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
- FIGURE 12 SPINAL CORD STIMULATOR (SCS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
- FIGURE 13 DEEP BRAIN STIMULATOR (DBS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
- FIGURE 14 SACRAL NERVE STIMULATOR (SNS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
- FIGURE 15 HYPOGLOSSAL NERVE STIMULATOR (HGNS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
- FIGURE 16 UNITED STATES OBSTRUCTIVE SLEEP APNEA NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
- FIGURE 17 UNITED STATES DRUG RESISTANT EPILEPSY NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
- FIGURE 18 UNITED STATES DEPRESSION NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
- FIGURE 19 UNITED STATES OVERACTIVE BLADDER NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
- FIGURE 20 UNITED STATES CHRONIC PAIN NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
- FIGURE 21 NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
- FIGURE 22 INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
- FIGURE 23 SPINAL CORD STIMULATION (SCS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
- FIGURE 24 DEEP BRAIN STIMULATION (DBS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
- FIGURE 25 SACRAL NERVE STIMULATION (SNS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
- FIGURE 26 VAGUS NERVE STIMULATION (VNS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
- FIGURE 27 HYPOGLOSSAL NERVE STIMULATION (HGNS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
- FIGURE 28 OTHER INVASIVE NEUROMODULATION GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
- FIGURE 29 NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 V/S 2029) (%)
- FIGURE 30 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
- FIGURE 31 NEUROMUSCULAR ELECTRICAL STIMULATION (NMES) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
- FIGURE 32 OTHER NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
- FIGURE 33 NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
- FIGURE 34 PAIN MANAGEMENT GLOBAL MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 35 CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET SHARE, BASED ON APPLICATION TYPE, (2022 V/S 2029) (%)
- FIGURE 36 GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET SHARE, BASED ON APPLICATION TYPE, (2022 V/S 2029) (%)
- FIGURE 37 NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
- FIGURE 38 HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC) GLOBAL MARKET SHARE, BASED ON END-USERS, (2022 V/S 2029) (%)
- FIGURE 39 CLINICS AND PHYSIOTHERAPY CENTERS GLOBAL MARKET SHARE, BASED ON END-USERS, (2022 V/S 2029) (%)
- FIGURE 40 OTHERS GLOBAL MARKET SHARE, BASED ON END-USERS, (2022 V/S 2029) (%)
- FIGURE 41 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN), CAGR (%)
- FIGURE 42 NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON GEOGRAPHY (2022) (%)
- FIGURE 43 NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCTS, (2022 V/S 2029) (%)
- FIGURE 44 NORTH AMERICA INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
- FIGURE 45 NORTH AMERICA NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
- FIGURE 46 NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
- FIGURE 47 NORTH AMERICA PAIN MANAGEMENT MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 48 NORTH AMERICA CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 49 NORTH AMERICA GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 50 NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BASED ON END USER (2022 V/S 2029) (%)
- FIGURE 51 NORTH AMERICA NEUROMODULATION DEVICES MARKET, BASED ON COUNTRY (2022 V/S 2029) (%)
- FIGURE 52 U.S. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
- FIGURE 53 U.S. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
- FIGURE 54 REST OF NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
- FIGURE 55 REST OF NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
- FIGURE 56 EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
- FIGURE 57 EUROPE INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
- FIGURE 58 EUROPE NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
- FIGURE 59 EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029)
- FIGURE 60 EUROPE PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 61 EUROPE CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 62 EUROPE GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 63 EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON END USERS (2022 V/S 2029) (%)
- FIGURE 64 EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
- FIGURE 65 GERMANY NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
- FIGURE 66 GERMANY NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS (2022 V/S 2029) ($MN)
- FIGURE 67 FRANCE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
- FIGURE 68 FRANCE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
- FIGURE 69 U.K. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
- FIGURE 70 U.K. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
- FIGURE 71 REST OF EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
- FIGURE 72 REST OF EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) (%)
- FIGURE 73 APAC NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
- FIGURE 74 APAC INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
- FIGURE 75 APAC NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
- FIGURE 76 APAC NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
- FIGURE 77 APAC PAIN MANAGEMENT MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 78 APAC CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 79 APAC GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 80 APAC GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON END USERS (2022 V/S 2029) (%)
- FIGURE 81 APAC NEUROMODULATION DEVICES MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
- FIGURE 82 JAPAN NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
- FIGURE 83 JAPAN NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
- FIGURE 84 CHINA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
- FIGURE 85 CHINA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
- FIGURE 86 INDIA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
- FIGURE 87 INDIA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
- FIGURE 88 REST OF APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
- FIGURE 89 REST OF APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
- FIGURE 90 ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
- FIGURE 91 ROW INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
- FIGURE 92 ROW NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
- FIGURE 93 ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
- FIGURE 94 ROW PAIN MANAGEMENT MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 95 ROW CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 96 ROW GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
- FIGURE 97 ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON END USER (2022 V/S 2029) (%)
- FIGURE 98 ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
- FIGURE 99 BRAZIL NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
- FIGURE 100 BRAZIL NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
- FIGURE 101 REST OF LATAM NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
- FIGURE 102 REST OF LATAM NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
- FIGURE 103 MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
- FIGURE 104 MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
- FIGURE 105 KEY GROWTH STRATEGIES, (2020-2022)
- FIGURE 106 SWOT: ABBOTT LABORATORIES
- FIGURE 107 SWOT: AXONICS INC.
- FIGURE 108 SWOT: BIOVENTUS
- FIGURE 109 SWOT: BOSTON SCIENTIFIC CORPORATION
- FIGURE 110 SWOT: INSPIRE MEDICAL SYSTEM, INC.
- FIGURE 111 SWOT: LABORIE MEDICAL TECHNOLOGY INC.
- FIGURE 112 SWOT: LIVANOVA PLC
- FIGURE 113 SWOT: MEDTRONIC PLC.
- FIGURE 114 SWOT: NEUROPACE, INC.
- FIGURE 115 SWOT: NEVRO CORPORATION
- 1 Abbott Laboratories
- 2 Algostim
- 3 Ates Medica Device Srl
- 4 Atrotech Oy
- 5 Attune Neurosciences
- 6 Auri- Stim Medical, Inc
- 7 Avery Biomedical Devices Inc.
- 8 Axilum Robotics
- 9 AxioBionics LLC
- 10 Axonics Inc.
- 11 Baldoni Neuromodulation
- 12 Beijing Pins Medical Co., Ltd.
- 13 Biocontrol Medical
- 14 Bioinduction Ltd.
- 15 Bioness Inc.
- 16 Bioventus Inc. (Bioness Inc.,)
- 17 BioWave
- 18 BlueWind Medical
- 19 Boston Scientific Corporation
- 20 Bottneuro
- 21 Brainsway Ltd.
- 22 Cafely
- 23 Cala Health
- 24 Cardia Care
- 25 Cochlear Ltd
- 26 Comphya
- 27 Cortec GmbH
- 28 Corveus Medical
- 29 CVRx
- 30 Cyberonics, Inc.
- 31 Cymedica Orthopedics
- 32 Desyncra Technologies
- 33 Djo Global (Colfax Corp.)
- 34 Dw Healthcare (Cefaly Technology)
- 35 DyAnsys
- 36 EB Neuro S.P.A.
- 37 electroCore
- 38 eNeura Inc.
- 39 Epineuron Technologies, Inc.
- 40 Gimer Medical
- 41 Greatbatch Medical
- 42 G-Therapeutics
- 43 Helius Medical Technologies
- 44 Heuro Canada
- 45 InnoCon Medical
- 46 Innovative Health Solutions.
- 47 Insai
- 48 Inspire Medical Systems
- 49 IntraPace
- 50 JumpStart Inc
- 51 Laborie Medical Technologies Inc. (Cogentix Medical)
- 52 Livanova Plc (Sorin Group)
- 53 Magnus Medical
- 54 Magstim TMS
- 55 Magventure A/S
- 56 Mainstay Medical
- 57 Medtronic Plc
- 58 MetaCure, Ltd
- 59 MicroTransponder Inc.
- 60 Nalu Medical
- 61 NDI Medical
- 62 NeoSync
- 63 Nesos
- 64 Neuralace Medical
- 65 NeurAxis
- 66 Neurocare Group GMBH
- 67 Neuroelectrics
- 68 NeuroEm Therapeutics Inc.
- 69 Neurolief Ltd.
- 70 NeuroMetrix
- 71 Neuronetics
- 72 Neuropace Inc.
- 73 Neuros Medical, Inc.
- 74 Neurosigma Inc
- 75 Neurovalens
- 76 Nevro Corporation
- 77 Nexstim Plc
- 78 Northstar Neuroscience
- 79 Nuraleve Inc
- 80 Nuvectra Corporation
- 81 Nyxoah SA
- 82 ODstock Medical
- 83 Olympic Ophthamalic Inc.
- 84 Onward Medical
- 85 Pathmaker Neurosystems Inc.
- 86 Phagenesis
- 87 Precidio Medical
- 88 Precisis AG
- 89 Pulvinar Neuro (Electromedical Products International, Inc,(EPI))
- 90 REMED Co., Ltd.
- 91 Rogue research
- 92 Saluda Medical
- 93 Salvia Bioelectronics
- 94 Sana Health
- 95 SceneRay Technologies
- 96 Set Point Medical
- 97 ShiraTronics
- 98 Signifier Medical Technologies Ltd
- 99 Sooma Oy
- 100 Soterix Medical
- 101 Spark Biomedical
- 102 SPR Therapeutics
- 103 Stimdia Medical Inc,
- 104 Stimwave LLC
- 105 Sublimed
- 106 Synapse Biomedical Inc.
- 107 Syneika
- 108 Theranica Bio-Electronics Ltd.
- 109 tVNS Technologies
- 110 Uroplasty, Inc.
- 111 Vertis Neurosciences
- 112 Ybrain, INC
- 113 ZOLL Medical Corporation (Respicardia, Inc.)
- 114 Zosano
- 115 Zynex Medical, Inc.